Severe Acute Respiratory Syndrome Coronavirus 2 and Respiratory Virus Sentinel Surveillance, California, USA, May 10, 2020-June 12, 2021
State and local health departments established the California Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Respiratory Virus Sentinel Surveillance System to conduct enhanced surveillance for SARS-CoV-2 and other respiratory pathogens at sentinel outpatient testing sites in 10 counties throughout California, USA. We describe results obtained during May 10, 2020‒June 12, 2021, and compare persons with positive and negative SARS-CoV-2 PCR results by using Poisson regression. We detected SARS-CoV-2 in 1,696 (19.6%) of 8,662 specimens. Among 7,851 specimens tested by respiratory panel, rhinovirus/enterovirus was detected in 906 (11.5%) specimens and other respiratory pathogens in 136 (1.7%) specimens. We also detected 23 co-infections with SARS-CoV-2 and another pathogen. SARS-CoV-2 positivity was associated with male participants, an age of 35-49 years, Latino race/ethnicity, obesity, and work in transportation occupations. Sentinel surveillance can provide useful virologic and epidemiologic data to supplement other disease monitoring activities and might become increasingly useful as routine testing decreases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Emerging infectious diseases - 28(2022), 1 vom: 19. Jan., Seite 9-19 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cooksey, Gail L Sondermeyer [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.01.2022 Date Revised 15.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3201/eid2801.211682 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334684544 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334684544 | ||
| 003 | DE-627 | ||
| 005 | 20231225224231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid2801.211682 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334684544 | ||
| 035 | |a (NLM)34932449 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cooksey, Gail L Sondermeyer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Severe Acute Respiratory Syndrome Coronavirus 2 and Respiratory Virus Sentinel Surveillance, California, USA, May 10, 2020-June 12, 2021 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2022 | ||
| 500 | |a Date Revised 15.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a State and local health departments established the California Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Respiratory Virus Sentinel Surveillance System to conduct enhanced surveillance for SARS-CoV-2 and other respiratory pathogens at sentinel outpatient testing sites in 10 counties throughout California, USA. We describe results obtained during May 10, 2020‒June 12, 2021, and compare persons with positive and negative SARS-CoV-2 PCR results by using Poisson regression. We detected SARS-CoV-2 in 1,696 (19.6%) of 8,662 specimens. Among 7,851 specimens tested by respiratory panel, rhinovirus/enterovirus was detected in 906 (11.5%) specimens and other respiratory pathogens in 136 (1.7%) specimens. We also detected 23 co-infections with SARS-CoV-2 and another pathogen. SARS-CoV-2 positivity was associated with male participants, an age of 35-49 years, Latino race/ethnicity, obesity, and work in transportation occupations. Sentinel surveillance can provide useful virologic and epidemiologic data to supplement other disease monitoring activities and might become increasingly useful as routine testing decreases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a California | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a United States | |
| 650 | 4 | |a coronavirus disease | |
| 650 | 4 | |a coronaviruses | |
| 650 | 4 | |a respiratory infections | |
| 650 | 4 | |a respiratory viruses | |
| 650 | 4 | |a sentinel surveillance | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a viruses | |
| 650 | 4 | |a zoonoses | |
| 700 | 1 | |a Morales, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Linde, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Schildhauer, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Guevara, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Gibb, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Jessie |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Bonin, Brandon J |e verfasserin |4 aut | |
| 700 | 1 | |a Arizmendi, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Lam-Hine, Tracy |e verfasserin |4 aut | |
| 700 | 1 | |a Tzvieli, Ori |e verfasserin |4 aut | |
| 700 | 1 | |a McDowell, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Kampen, Kirstie M |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez, Denise L |e verfasserin |4 aut | |
| 700 | 1 | |a Ennis, Josh |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Linda S |e verfasserin |4 aut | |
| 700 | 1 | |a Oren, Eyal |e verfasserin |4 aut | |
| 700 | 1 | |a Hatada, April |e verfasserin |4 aut | |
| 700 | 1 | |a Molinar, Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Frederick, Matt |e verfasserin |4 aut | |
| 700 | 1 | |a Han, George S |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez, Martha |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a McGrath, Alana |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Nga Q |e verfasserin |4 aut | |
| 700 | 1 | |a Boyd, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Bertolucci, Regina M |e verfasserin |4 aut | |
| 700 | 1 | |a Corrigan, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Brodine, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Austin, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Roach, William R K |e verfasserin |4 aut | |
| 700 | 1 | |a Levin, Robert M |e verfasserin |4 aut | |
| 700 | 1 | |a Tyson, Brian M |e verfasserin |4 aut | |
| 700 | 1 | |a Pry, Jake M |e verfasserin |4 aut | |
| 700 | 1 | |a Cummings, Kristin J |e verfasserin |4 aut | |
| 700 | 1 | |a Wadford, Debra A |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Seema |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging infectious diseases |d 1995 |g 28(2022), 1 vom: 19. Jan., Seite 9-19 |w (DE-627)NLM088704254 |x 1080-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:1 |g day:19 |g month:01 |g pages:9-19 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3201/eid2801.211682 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 1 |b 19 |c 01 |h 9-19 | ||